Randomized phase III study 306 Adjunctive perampanel for refractory partial-onset seizures

Neurology

Volumn 78, Issue 18, 2012, Pages 1408-1415

  Krauss, G L ^a   Serratosa, J M ^b   Villanueva, V ^c   Endziniene, M ^d   Hong, Z ^e   French, J ^f   Yang, H ^g   Squillacote, D ^g   Edwards, H B ^a   Zhu, J ^g   Laurenza, A ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^e FUDAN UNIVERSITY   (China)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADD ON THERAPY; ADULT; ARTICLE; CHILD; COMPLEX PARTIAL SEIZURE; CONTROLLED STUDY; CONVULSION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; VERTIGO; WEIGHT GAIN;

EID: 84860755687     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318254473a     Document Type: Article

References (17)

1. Tokuhara N, Hatakeyama S, Amino H, Hanada T, Nishizawa Y. Pharmacological profile of perampanel: A novel, non-competitive selective AMPA receptor antagonist. Presented at the 60th annual meeting of the American Academy of Neurology, April 12-19, 2008, Chicago, IL.
2. Hashizume Y, Hanada T, Ogasawara A, Ueno M, Nishizawa Y. Anticonvulsant activity of perampanel, a selective AMPA receptor antagonist, in rodent models of epileptic seizure. J Neurol 2008;255 (suppl 2):1-235.
3. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-1340.
4. Rogawski MA, Loscher W. Neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-564.
5. Zilles K, Qu MS, Kohling R, Speckmann EJ. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: Quantitative in vitro receptor autoradiography. Neuroscience 1999;94:1051-1061. (Pubitemid 29509672)
6. Vollmar W, Gloger J, Berger E. RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients. Neurobiol Dis 2004;15:371-379. (Pubitemid 38296768)
7. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug treatment. Neurotherapeutics 2007;4:18-61. (Pubitemid 46107329)
8. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11:56-63.
9. Krauss G, Biton V, Klapper J, Bar M, Rektor I, Squillacote D. Determination of maximum tolerated dose (MTD), safety, efficacy, and pharmacokinetics (PK) of perampanel, a selective AMPA receptor antagonist, as adjunctive therapy in subjects with refractory partial seizures. Presented at the 62nd annual meeting of the American Epilepsy Society, December 5-9, 2008, Seattle, WA.
10. Krauss G, Biton V, Klapper J, et al. Determination of tolerability, safety and efficacy of perampanel, a selective AMPA receptor antagonist, as adjunctive therapy in subjects with refractory partial seizures. Poster 476 presented at the 28th International Epilepsy Congress, June 28-July 2, 2009, Budapest.
11. ILAE. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
12. Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Presented at the 63rd annual meeting of the American Epilepsy Society, December 4-8, 2009, Boston, MA.
13. Cramer J, Ben-Menachem E, French J. Review of treatment options for refractory epilepsy: New medications and vagal nerve stimulation. Epilepsy Res 2001;47:17-25. (Pubitemid 32973644)
14. Johannessen SI, Ben-Menachem E. Management of focalonset seizures: An update on drug treatment. Drugs 2006; 66:1701-1725. (Pubitemid 44427434)
15. Chappell AS, Sander JW, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;11:58:1680-1682. (Pubitemid 34602903)
16. French J, Elger C, Goldberg-Stern H, et al. Global phase III trial of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures. Presented at the 63rd annual meeting of the American Academy of Neurology, April 9-16, 2011, Honolulu, HI.
17. French J, Elger C, Goldberg-Stern H, et al. Use of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: Results of a global phase III study. Presented at the 29th International Epilepsy Congress, August 28-September 1, 2011, Rome.